WO2013124749A1 - Nouveau polymorphe d'étéxilate de dabigatran - Google Patents

Nouveau polymorphe d'étéxilate de dabigatran Download PDF

Info

Publication number
WO2013124749A1
WO2013124749A1 PCT/IB2013/050657 IB2013050657W WO2013124749A1 WO 2013124749 A1 WO2013124749 A1 WO 2013124749A1 IB 2013050657 W IB2013050657 W IB 2013050657W WO 2013124749 A1 WO2013124749 A1 WO 2013124749A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
carbonyl
formula
amino
phenylamino
Prior art date
Application number
PCT/IB2013/050657
Other languages
English (en)
Inventor
Venkat Raman JAYARAMAN
Samir Patel
Samir Mistry
Mukesh Timbadiya
Bhupendra Parmar
Parimal TAMBOLI
Jignesh Patel
Original Assignee
Alembic Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Pharmaceuticals Limited filed Critical Alembic Pharmaceuticals Limited
Publication of WO2013124749A1 publication Critical patent/WO2013124749A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the invention relates to new polymorphs of the active substance Dabigatran etexilate, processes for the preparation thereof and the use thereof as pharmaceutical compositions.
  • This active substance with the chemical formula I
  • the compound of formula I is only converted into the actual effective compound, namely the compound of formula II, in the body.
  • the main fields of application of the compound of chemical formula I are the post-operative prophylaxis of deep vein thrombosis and the prevention of stroke.
  • Dabigatran etexilate was first described in WO 199837075 by Hauel et al.
  • dabigatran etexilate of the formula II is prepared in an analogous manner to the process described in Example 90 by reacting l-methyl-2- [N-(4-amidino-pheny])-aminomethyl]-5-benzirnidazol-carbonate-N-(2-pyridyl)-A)-[2- (ethoxy- carbonyl)-ethyl]-amid hydrochloride and hexyl chloroformate.
  • the thus-formed base is characterized by thin layer chomatography and mass spectrometry. No information is provided in the description relating to the crystallographic properties of the dabigatran etexilate base.
  • salts of dabigatran etexilate are described, such as the hydrochloride, citrate, tartarate, malonate, maleate and salicilate salts. These salts are not characterized by powder X-ray diffraction patterns, only by differential scanning calorimetry curves. The melting points ranked in order are as follows: 135°C, 170°C, 160°C, 100°C, 120°C, and 155 °C.
  • WO20061314913 polymorphic forms of the dabigatran etexilate base are described.
  • the polymorphic forms obtained by crystallization are characterized by X-ray powder diffraction patterns, differential scanning calorimetry curves and thermogravimetric measurements data.
  • WO 2008043759 further dabigatran etexilate salts and polymorphic forms thereof are described, such as two polymorph (I and II) of the salt formed with phosphoric acid, two polymorph (III and IV) of the salt formed with fumaric acid, three polymorph (I, II and V) of the salt formed with oxalic acid, three polymorph (II, V and VI) of the salt formed with hydrogen chloride and four polymorph (I, V, VI and VII) of the salt formed with p- toluenesulfonic acid.
  • the polymorphic forms are characterized by X-ray powder diffraction pattern.
  • Form IV of the salt formed with fumaric acid and four Forms (I, V, VI and VII) of the salt formed with p-toluenesulfonic acid are characterized by differential scanning calorimetry curves, too.
  • WO2008059029 two further anhydrous forms and three solvates of the dabigatran etexilate base are described.
  • the anhydrous forms III and IV, the monohydrate forms I and II and the nitrobenzene solvate form I are characterized by X-ray powder diffraction pattern and differential scanning calorimetry curves.
  • the aim of the invention is to provide new polymorphs of the compound of formula I having advantageous properties for pharmaceutical use.
  • examples of these parameters are the stability of effect of the starting substance under different ambient conditions, stability in the course of the preparation of the pharmaceutical formulation and stability in the final compositions of the pharmaceutical preparation.
  • the pharmaceutical active substance used to prepare the pharmaceutical compositions should therefore have high stability, which should also be guaranteed even under different environmental conditions. This is absolutely essential to prevent the use of pharmaceutical compositions which contain, in addition to the active substance itself, breakdown products thereof, for example. In such cases the content of active substance found in the pharmaceutical formulations might be less than specified.
  • the absorption of moisture reduces the content of pharmaceutically active substance as a result of the increased weight caused by the uptake of water.
  • Pharmaceutical compositions with a tendency to absorb moisture have to be protected from moisture during storage, e.g.
  • a pharmaceutically active substance should be only slightly hygroscopic.
  • the problem of the present invention is to provide a pharmaceutically active substance which not only is characterised by high pharmacological potency but also satisfies the above-mentioned physicochemical requirements as far as possible.
  • the object of the present invention to provide novel polymorph of 3-[(2- ⁇ [4- (hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl ⁇ - 1 -methyl- 1 H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate) referred to as form A.
  • Another object of the present invention to provide process for the preparation of novel polymorph of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl ⁇ - 1 -methyl- lH-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate) referred to as form A
  • the present invention to provide novel polymorph of 3-[(2- ⁇ [4- (hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ - 1 -methyl- 1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate) referred to as form A.
  • the present invention relates to the above-mentioned polymorphic form of the active substance 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)- phenylamino] - methyl ⁇ - 1 -methyl- 1 H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] - propionic acid ethyl ester, in crystalline form, referred to as form A characterised by XRD.
  • the present invention relates to the above-mentioned polymorphic form of the active substance 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)- phenylamino] - methyl ⁇ - 1 -methyl- 1 H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] - propionic acid ethyl ester, in crystalline form, referred to as form A characterised by TGA.
  • the present invention relates to the above-mentioned polymorphic form of the active substance 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)- phenylamino] - methyl ⁇ - 1 -methyl- 1 H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] - propionic acid ethyl ester, in crystalline form, referred to as form A characterised by XRD, DSC, TGA Fig.
  • Fig. 1 shows the X-ray powder diffraction pattern of new polymorph Form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ - 1 -methyl- 1 H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate).
  • Fig. 1 shows the X-ray powder diffraction pattern of new polymorph Form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ - 1 -methyl- 1 H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate).
  • Fig. 3 shows the TGA of new polymorph Form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino- imino-methyl)-phenylamino] - methyl ⁇ - 1 -methyl- 1 H-benzimidazole-5-carbonyl)-pyridin- 2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate).
  • crystallizing means crystallizing compounds using methods known in the art. For example either reducing the volume of the solvent with respect to solute or decreasing the temperature of the solution or using both so as to crystallize the compound.
  • treating refers to suspending, dissolving or mixing and contacting or reacting of product with solvent or reagents followed by isolating product by removal of reagents and solvents.
  • the term "triturating” as used hereinabove refers to suspending product in solvent and stirring for period of time sufficient for surface contact of solid with solvent and then filtering the compound from the mixture.
  • the first embodiment, of the present invention relates to the novel polymorph of new polymorph Form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ - 1 -methyl- 1 H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] -propionic acid ethyl ester compound of formula I (dabigatran etexilate).
  • the present invention relates to a novel polymorph Form A of 3- [(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] - methyl ⁇ - 1 -methyl- 1 H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate) characterized by an X-ray powder diffraction (XRD) pattern having peaks expressed at 2 ⁇ at about 4.9, 8.8, 9.2, 9.7, 10.4, 12.7, 13.3, 13.8, 14.7, 15.5, 18.0, 18.9, 20.1 , 20.8, 21.6, 22.3, 22.7, 23.3, 23.8, 24.2, 24.7, 26.8, 27.4, 28.2, 28.7, 29.5, and 36.6
  • the present invention relates to novel polymorph Form A of 3- [(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino] - methyl ⁇ - 1 -methyl- 1 H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester compound of formula I (dabigatran etexilate), characterised by TGA characterized is depicted in Fig. 3.
  • the present invention relates to novel polymorph Form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ - 1 -methyl- 1 H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] -propionic acid ethyl ester compound of formula I (dabigatran etexilate), characterised by XRD, DSC, TGA which is depicted in Fig. 1 to 3.
  • the invention also relates to the methods of selectively producing the polymorphic form as well as the modifications which may be obtained by these methods.
  • the present invention relates to process for preparation of the form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ -1 - methyl- lH-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] -propionic acid ethyl ester compound of formula I (dabigatran etexilate) is obtained by
  • the present invention provides a process for the preparation of form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ -!- methyl- lH-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] -propionic acid ethyl ester compound of formula I (dabigatran etexilate) which comprising step of
  • the present invention provides a process for the preparation of form A of 3-[(2- ⁇ [4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl ⁇ -1 - methyl- lH-benzimidazole-5-carbonyl)-pyridin-2-yl-amino] -propionic acid ethyl ester compound of formula I (dabigatran etexilate) which comprising step of :

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne un nouveau polymorphe d'ester éthylique d'acide 3-[(2-{[4-(hexyloxycarbonylaminoimino-méthyl)-phénylamino]-méthyl}-1-méthyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionique.
PCT/IB2013/050657 2012-02-20 2013-01-25 Nouveau polymorphe d'étéxilate de dabigatran WO2013124749A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN513/MUM/2012 2012-02-20
IN513MU2012 2012-02-20

Publications (1)

Publication Number Publication Date
WO2013124749A1 true WO2013124749A1 (fr) 2013-08-29

Family

ID=49005079

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/050657 WO2013124749A1 (fr) 2012-02-20 2013-01-25 Nouveau polymorphe d'étéxilate de dabigatran

Country Status (1)

Country Link
WO (1) WO2013124749A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020546A3 (fr) * 2012-07-31 2014-03-27 Ranbaxy Laboratories Limited Formes cristallines d'étexilate de dabigatran et leur procédé de préparation
WO2015033353A3 (fr) * 2013-09-03 2015-06-04 Laurus Labs Private Limited Nouveaux sels d'addition d'acide d'étéxilate de dabigatran et procédé pour la préparation de ceux-ci
WO2015124764A1 (fr) 2014-02-24 2015-08-27 Erregierre S.P.A. Procédé de synthèse de dabigatran étexilate mésylate, intermédiaires de ce procédé et nouveau polymorphe de dabigatran étexilate
WO2017151042A1 (fr) * 2016-03-02 2017-09-08 Marvel Pharma Consulting Compositions pharmaceutiques pour thérapie anticoagulante à la demande
WO2023174090A1 (fr) * 2022-03-15 2023-09-21 青岛华麒医药科技创新发展有限公司 Cocristal d'étexilate de dabigatran et son procédé de préparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059029A2 (fr) * 2006-11-16 2008-05-22 Boehringer Ingelheim International Gmbh Nouveaux polymorphes d'éthyle 3-[(2-{[4- (hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate
CN101189224A (zh) * 2005-06-04 2008-05-28 贝林格尔·英格海姆国际有限公司 3-[(2-{[4-(己氧基羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯的多晶型

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189224A (zh) * 2005-06-04 2008-05-28 贝林格尔·英格海姆国际有限公司 3-[(2-{[4-(己氧基羰基氨基-亚氨基-甲基)-苯基氨基]-甲基}-1-甲基-1h-苯并咪唑-5-羰基)-吡啶-2-基-氨基]-丙酸乙酯的多晶型
WO2008059029A2 (fr) * 2006-11-16 2008-05-22 Boehringer Ingelheim International Gmbh Nouveaux polymorphes d'éthyle 3-[(2-{[4- (hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE IP.COM PRIOR ART DATABASE 14 February 2011 (2011-02-14), "Disclosed Anonymously, Polymorphic forms of Dabigatran etexilate", retrieved from http://priorarldatabase.ocmJIPCOM/000204135 accession no. PCOM000204135D. *
HAUEL N. H. ET AL.: "Structure-Based Design of Novel Potent Nonpeptide Thrombin Inhibitors", J. MED. CHEM., vol. 45, 2002, pages 1757 - 1766, XP001098844 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014020546A3 (fr) * 2012-07-31 2014-03-27 Ranbaxy Laboratories Limited Formes cristallines d'étexilate de dabigatran et leur procédé de préparation
WO2015033353A3 (fr) * 2013-09-03 2015-06-04 Laurus Labs Private Limited Nouveaux sels d'addition d'acide d'étéxilate de dabigatran et procédé pour la préparation de ceux-ci
WO2015124764A1 (fr) 2014-02-24 2015-08-27 Erregierre S.P.A. Procédé de synthèse de dabigatran étexilate mésylate, intermédiaires de ce procédé et nouveau polymorphe de dabigatran étexilate
WO2017151042A1 (fr) * 2016-03-02 2017-09-08 Marvel Pharma Consulting Compositions pharmaceutiques pour thérapie anticoagulante à la demande
WO2023174090A1 (fr) * 2022-03-15 2023-09-21 青岛华麒医药科技创新发展有限公司 Cocristal d'étexilate de dabigatran et son procédé de préparation

Similar Documents

Publication Publication Date Title
TWI418553B (zh) ３－〔（２－｛〔４－（己氧基羰基胺基－亞胺基－甲基）－苯胺基〕－甲基｝－１－甲基－１ｈ－苯并咪唑－５－羰基）－吡啶－２－基－胺基〕－丙酸乙酯－甲磺酸鹽及其作為藥物之用途
US20100144796A1 (en) New polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino- methyl)-phenylamino]-methyl-1-methyl-1h-benzimidazole-5-carbonyl) -pyridin-2-yl-amino]-propionate
JP5129132B2 (ja) ４−メチル−ｎ−［３−（４−メチル−イミダゾル−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの塩
TWI406661B (zh) ４-甲基-ｎ-〔３-（４-甲基-咪唑-１-基）-５-三氟甲基-苯基〕-３-（４-吡啶-３-基-嘧啶-２基胺基）-苯甲醯胺之結晶型
KR101019451B1 (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
US20060276513A1 (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
JP6158811B2 (ja) ４−［５−（ピリジン−４−イル）−１ｈ−１，２，４−トリアゾール−３−イル］ピリジン−２−カルボニトリルの結晶多形およびその製造方法
US20060247278A1 (en) Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
JP6609065B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミンの新規な酸付加塩
WO2011110876A1 (fr) Nouveaux sels pour fabrication de compositions pharmaceutiques
WO2012027543A1 (fr) Formes solides de dabigatran étexilate et de dabigatran étexilate mésylate et leurs méthodes de préparation
CA2803559A1 (fr) Sels de nilotinib et formes cristallines de ceux-ci
WO2008043759A1 (fr) Sels physiologiquement acceptables de l'ester éthylique de l'acide 3-[(2-{[4-(hexyloxycarbonylamino-imino-méthyl)-phénylamino]-méthyl}-1-méthyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionique.
KR20030026979A (ko) 디시아노피리딘 유도체를 포함하는 의약
JP2005529114A (ja) カリウムチャンネル機能のヘテロ環インヒビター
WO2013124749A1 (fr) Nouveau polymorphe d'étéxilate de dabigatran
WO2013111163A2 (fr) Procédé de préparation de dabigatran étéxilate mésylate et polymorphes d'intermédiaires de celui-ci
MX2011001135A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-m etoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos.
EP2086962A1 (fr) 1- [ ( 4 -chlorophényl) amide 5-{[2-fluoro-4- (2-oxo-2h-pyridin-1-yl) -phényl]amide) d'acide (r) -5-méthyl-4, 5-dihydro- pyrazole-1, 5-dicarboxylique servant d'inhibiteur du facteur xa
US8252926B2 (en) Process for the preparation of imatinib base
TW201742866A (zh) 一種腎外髓質分泌鉀通道抑制劑的可藥用鹽
WO2013144971A1 (fr) Nouvelles formes solides de bisulfate et de mésylate d'étéxilate de dabigatran, et leurs procédés de préparation
KR20130041381A (ko) ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노－메틸）－페닐아미노］－메틸｝ －１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］－프로피온산 에틸에스테르－메탄설포네이트 및 이를 포함하는 약제학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13751551

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13751551

Country of ref document: EP

Kind code of ref document: A1